June 17, 2025 01:37 PM EDT
Pharma
FDA+

FDA ap­proves CSL’s pro­phy­lac­tic for se­vere swelling con­di­tion

Nicole DeFeudis

Editor

CSL Behring won FDA ap­proval on Mon­day for its once-month­ly pre­ven­tive treat­ment for a rare, ge­net­ic con­di­tion that caus­es swelling episodes.

An­dem­bry is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi-backed Welsh biotech se­cures $140M for neu­ropsy­chi­a­try pipeline

Af­ter a qui­et year, Xaira un­wraps some of its AI re­search, eye­ing a vir­tu­al cell

Ac­tio gets $66M for ex­per­i­men­tal epilep­sy and Char­cot-Marie-Tooth treat­ments

FDA un­veils one-year pi­lot to speed some new drugs to mar­ket in just one month

Or­phan drug, PBM changes are ex­clud­ed from Sen­ate ver­sion of Trump tax bill

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times